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matching data over 2000-2010, 17,088 additional cases, 337 additional 
hospitalizations and 168 additional deaths could potentially be avoided annually 
with QIV versus TIV. There would be no additional benefits for well-matched 
years 2000-03 and 2009-10. In mismatched years benefits could range from 
minor, such as 2003-4 (100% mismatched, 0.4% influenza-B circulation) where 
578 additional cases, 11 additional hospitalizations and 6 additional deaths 
potentially avoided to significant impact, such as 2005-6 (98.8% mismatched, 70% 
influenza-B circulation) with 100,296 additional cases, 1,976 additional 
hospitalizations and 988 additional deaths potentially avoided. CONCLUSIONS: 
Our analysis predicts that using recent influenza-B circulation and vaccine 
matching data, in 6 out of 10 years, a strategy of vaccination with QIV would 
have been more effective than TIV in reducing the number of influenza cases, 
and associated hospitalisations and deaths. Retrospective analysis of influenza 
circulation suggests that co-circulation of influenza-B lineages persists and that 
mismatch is frequent and unpredictable. The use of QIV might aid in reducing 
the associated burden of mismatched influenza-B.  
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OBJECTIVES: Meningococcal disease (MD) is a serious public health problem 
worldwide. It mainly affects low-income countries with higher impact in the 
‘meningococcal belt’ located at the African Sub Sahara. Children younger than 5 
years old are the most affected age group, with the highest incidence in the first 
year of life. Our aim is to evaluate the cost-effectiveness of the introduction of 
routine vaccination with a tetravalent meningococcal conjugate vaccine (MCV-4) 
in the Colombian EPI. METHODS: An age-dependent Markov model, which 
followed a cohort of children under one year of age up to their life expectancy, 
was developed. Parameters of occurrence and care costs were based on data 
from National Surveillance System, official data sources, and literature review. 
Serotype coverage was taken from SIREVA NM Colombia surveillances from 2007 
to 2010. A 3 + 1 schedule and a vaccination price of US$ 30.00 per dose were 
assumed in the base case, compared against no vaccination (only treatment the 
disease). All cost are expressed in 2011 US dollars. RESULTS: Introduction of 
MCV-4 would avoid 34 cases of meningococcal meningitis (MM), 27 cases of 
meningococcal sepsis, and 10 deaths in the lifespan of each infant’s cohort 
evaluated. MCV-4 vaccination avoids 126 years of life (LY), or 165 disability 
adjusted life years (DALYs). Vaccination would costs raises to US$ 71 million. The 
ICER of vaccination strategy compared to no vaccination was estimated at US$ 
441,998, which is very higher than the Colombian GPD (US$ 6,883). 
CONCLUSIONS: Routine vaccination against Neisseria meningitides with MCV-4in 
Colombia would not be cost-effective with tetravalent conjugate vaccine in the 
base case analysis.  
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OBJECTIVES: Streptococcus pneumoniae causes significant morbidity and 
mortality worldwide in both children and adults. The aim of this analysis is to 
evaluate the cost-effectiveness of vaccinating colombian population over 50 
years with 13-valent pneumococcal conjugated vaccine (PCV 13) from the 
institutional perspective in Colombia. METHODS: A Markov model was adapted 
to Colombian settings, using a time horizon of 5 years (3% annual discount rate). 
Comparators were PCV13, PPSV23 and no vaccination, vaccine coverage was 70%. 
Population size over 50 years of a Colombian insurance institution (n: 775,301) 
adjusted according with Colombian data was included, transition probabilities 
were extracted from a literature review, medical costs were taken from a local 
study developed by the “Fundación Cardio Infantil”, vaccines costs were taken 
from local report (SISMED), the diseases incidence was retrieved from literature 
(Castañeda et al. 2010, Dickinson et al 2001), vaccines efficacies were taken from 
literature (for PCV13 children data from PCV7 studies were adjusted by 
immunosenescence) and costs are expressed in 2012 US$. Effectiveness 
measures were the number of pneumococcal diseases and deaths prevented, as 
well as life years (LY) gained saved. Probabilistic sensitivity analyses were 
performed. RESULTS: Over a 5-year period, vaccinating with PCV13 prevents 
1,427 cases of invasive pneumococcal disease compared to PPSV23 and 1847 
compared no vaccination; 1691 and 1470 cases of invasive pneumonia and 188 
and 256 deaths, respectively. PCV13 saves 101,564 LY’s compared to PPSV23 and 
92,261 LY’s compared to no vaccination. Total expected costs (vaccination + 
medical costs) were US$164.0M for PCV13, US$ 164.4 PPSV23 and US$155.0M for 
no vaccination. CONCLUSIONS: Vaccinating adults over 50 years with PCV13 in a 
Colombian insurance institution is a cost-saving alternative in comparison to 
PPSV23 and a cost-effectiveness alternative to no vaccination (ICER = US$ 96.6 
/LY).  
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OBJECTIVES: Streptococcus pneumoniae causes significant morbidity and 
mortality worldwide in both children and adults. The aim of this analysis is to 
evaluate the cost-effectiveness of vaccinating the Bogota adult citizens (over 50 
years) with 13-valent pneumococcal conjugated vaccine (PCV 13) versus 23-
valent pneumococcal polysaccharide vaccine (PPSV23) and no vaccination from 
the public payer’s perspective in Colombia. METHODS: A Markov model was 
adapted to the Colombian public setting, using a time horizon of 4 years (3% 
annual discount rate). Comparators were PCV13, PPSV23 and no vaccination, 
vaccine coverage of 70% and projected Colombian population for 2013 were 
assumed, transition probabilities were extracted from literature review, medical 
costs were taken from a local study developed by the “Fundacion CardioInfantil”; 
vaccine prices were taken from the PAHO revolving fund price list, vaccines 
efficacies were taken from literature (for PCV13 children data from PCV7 studies 
were adjusted by immunosenescence), diseases incidences were retrieved from 
literature (Castañeda et al. 2010, Dickinson et al 2001) and costs were expressed 
in 2012 US$. Effectiveness measures were the number of pneumococcal diseases 
and deaths prevented, as well as life years (LY) saved. RESULTS: Over a 4-year 
period, vaccinating with PCV13 and PPSV23 against no vaccination prevents 2587 
and 1804 cases of invasive pneumococcal disease; 2365 and 11 cases of invasive 
pneumonia and 357 and 139 deaths respectively. PCV13 saves 518 LY’s compared 
to PPSV23 and 44.9 LY’s compared to no vaccination. Total expected saving 
(vaccination + medical costs) for PCV13 was US$5.8M against PPSV23 and US$3.2 
against no vaccination (total expected costs: US$54.5M; US$60.3M and US$57.7M 
respectively). CONCLUSIONS: Vaccinating adults over 50 years with PCV13 in 
Bogota is a cost-saving alternative in comparison to PPSV23 and no vaccination 
(US$3.5 and US$1.9 savings per patient, respectively). Study findings could 
support the decision-making process in favor of PCV13.  
 
PIN61  
COST-EFFECTIVENESS ANALYSIS OF PNEUMOCOCCAL CONJUGATE 
VACCINATION IN URBAN CHINA  
Liu G1, Zhu L2, Deng J2, Fu Y2, Chu Y2, Jin X2, Shi Q3 
1Peking University, Beijing, China, 2China Center for Health Economic Research, Beijing, China, 
3Pfizer China, Shanghai, China  
OBJECTIVES: To evaluate the cost-effectiveness results of introducing PCV7 into 
City Immunization Programs in 7 urban China. METHODS: Six health status 
contained pneumococcal meningitis (inpatient), pneumococcal septicemia 
(inpatient), pneumonia (all-cause, inpatient), pneumonia (all-cause, outpatient), 
mild otitis media (all-cause, outpatient) and sever otitis media (all-cause, 
outpatient )were considered. Age-specific cost was collected from electronic 
patient records (2010) from 14 hospitals in 7 cities in China. Two hospitals in 
each city was selected (1 Children’s Hospital, 1 Comprehensive Hospitals) and 7 
field cities including Beijing, Guangzhou, Shenzhen, Wuhan, Xi’an, Chengdu and 
Shenyang were enrolled. Direct medical cost included registry fee, medications, 
diagnostic tests fee, and hospitalization expenditure. A discount rate of 5% was 
applied. One-way sensitivity analyses were performed to evaluate the sensitivity 
of the results to data inputs. RESULTS:   As Category II vaccinePCV7 was not cost 
effective due to the private market unit price and low penetration rate. However, 
vaccination of children under 2 years old from 7 urban China in a CIP is 
estimated to prevent 366,337 cases from infection and 3,415 cases from death 
compared to no vaccination. From a payer perspective, a PCV7 CIP had an ICER of 
RMB17, 977/QALY in Beijing, RMB79,180/ QALY in Chengdu, RMB72,406/QALY in 
Guangzhou, RMB70,896/QALY in Shenyang,RMB69,792/QALY in Shenzhen, 
RMB64,152/QALY in Wuhan and RMB76,864/ QALY in Xian. CONCLUSIONS: The 
empirical results show that under the current situation with a 860 Yuan/ dose 
vaccination price and a 85% vaccination rate, when take PCV7 into the city 
immunization plan, the spending of the cost is worth in Beijing, Guangzhou and 
Shenzhen and is acceptable in Wuhan, Shenyang, Chengdu and Xi’an.  
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OBJECTIVES: Trivalent influenza vaccines contain two influenza A and one 
influenza B strains. The Food and Drug Administration has approved live 
attenuated and inactivated quadrivalent vaccines (containing two influenza A 
and both influenza B strains). Our aim was to compare the cost-effectiveness of 
vaccination with quadrivalent versus trivalent seasonal influenza vaccines. 
METHODS: A dynamic transmission model was used to estimate the age 
stratified temporal trend in influenza virus infection incidence. The population 
was divided into 5 subgroups: Susceptible, Exposed, Infectious, Recovered, and 
Vaccinated. We estimated health service resource utilisation from published 
disease-specific probabilities of consulting a primary care physician, 
hospitalization, and death. Disease burden was expressed in clinical (health 
service utilization and death), quality of life, and economic terms. Both a payer 
and societal perspectives were adopted. We compared the costs and outcomes of 
quadrivalent vaccination with those of trivalent vaccination, assuming price 
parity between vaccines. All costs and benefits were discounted at a rate of 3% 
per annum. Probabilistic sensitivity analyses were conducted. RESULTS: Adding 
a second influenza B strain to the trivalent seasonal influenza vaccines at the 
same vaccine prices was estimated to be cost-saving in the US. Estimated mean 
annual cost savings totalled $3.9 billion (societal perspective) and $1.6 billion 
(third-party payer perspective). On average, annual clinical benefits included 
over 13.5 million averted infections, over 510,000 averted primary care 
consultations, approximately 80,000 averted hospitalizations and 5,000 deaths 
prevented. The quadrivalent vaccines dominated their trivalent equivalents, 
saving cost and generating QALY’s. All sensitivity analyses were cost-saving. 
